The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Telling Your Date You Have Hepatitis C

Back to News Homepage

Next

Exciting Development in Search for Hepatitis C Vaccine

Breaking News: FDA Approves New Treatment for Hep C (Genotype 1)

November 25, 2013

Print this page

Janssen Therapeutics’ OLYSIO™ (simeprevir) has been approved by the FDA. It is a prescription medicine used with other antiviral medicines to treat genotype 1 chronic hepatitis C in adults. Learn more about how OLYSIO™ works.

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO™ (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. OLYSIO™ may benefit patients with chronic hepatitis C, including those who are treatment naive or who have failed prior interferon-based therapy.

Chronic hepatitis C is a blood-borne infectious disease of the liver that affects approximately 3.2 million people in the United States.

Continue reading this entire article:
http://www.news-medical.net/news/20131123/FDA-approves-OLYSIO-%28simeprevir%29-for-treatment-of-chronic-hepatitis-C-infection.aspx

28 Comments
Share
Share

Previous

Telling Your Date You Have Hepatitis C

Back to News Homepage

Next

Exciting Development in Search for Hepatitis C Vaccine

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.